SAGE
Sage Therapeutics
SAGE
SAGE
Delisted
SAGE was delisted on the 30th of July, 2025.
248 hedge funds and large institutions have $4.71B invested in Sage Therapeutics in 2018 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 91 increasing their positions, 88 reducing their positions, and 58 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
32% less capital invested
Capital invested by funds: $6.93B → $4.71B (-$2.22B)
45% less first-time investments, than exits
New positions opened: 32 | Existing positions closed: 58
Holders
248
Holding in Top 10
6
Calls
$129M
Puts
$93.6M
Top Buyers
| 1 | +$48.4M | |
| 2 | +$42.3M | |
| 3 | +$29.1M | |
| 4 |
Bank of New York Mellon
New York
|
+$27.1M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$25.7M |
Top Sellers
| 1 | -$80.2M | |
| 2 | -$49.6M | |
| 3 | -$29.3M | |
| 4 |
Millennium Management
New York
|
-$22M |
| 5 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$21.6M |